Peter Ordentlich
Gründer bei SYNDAX PHARMACEUTICALS, INC.
Vermögen: 5 451 $ am 30.04.2024
Aktive Positionen von Peter Ordentlich
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SYNDAX PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2013 | - |
Gründer | 11.10.2005 | - |
Karriereverlauf von Peter Ordentlich
Ehemalige bekannte Positionen von Peter Ordentlich
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | - | - |
The Salk Institute for Biological Studies | Corporate Officer/Principal | - | - |
Ausbildung von Peter Ordentlich
University of Pennsylvania | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sektoral
Consumer Services | 3 |
Health Technology | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SYNDAX PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Börse
- Insiders
- Peter Ordentlich
- Erfahrung